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Abstract
Breast cancer is the most common malignancy in women and is responsible for hundreds of thousands of deaths annually.
As with most cancers, it is a heterogeneous disease and different breast cancer subtypes are treated differently.
Understanding the difference in prognosis for breast cancer based on its molecular and phenotypic features is one avenue
for improving treatment by matching the proper treatment with molecular subtypes of the disease. In this work, we
employed a competition-based approach to modeling breast cancer prognosis using large datasets containing genomic
and clinical information and an online real-time leaderboard program used to speed feedback to the modeling team and to
encourage each modeler to work towards achieving a higher ranked submission. We find that machine learning methods
combined with molecular features selected based on expert prior knowledge can improve survival predictions compared to
current best-in-class methodologies and that ensemble models trained across multiple user submissions systematically
outperform individual models within the ensemble. We also find that model scores are highly consistent across multiple
independent evaluations. This study serves as the pilot phase of a much larger competition open to the whole research
community, with the goal of understanding general strategies for model optimization using clinical and molecular profiling
data and providing an objective, transparent system for assessing prognostic models.
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Introduction
Breast cancer remains the most common malignancy in females,
with more than 200,000 cases of invasive breast cancer diagnosed
in the United States annually [1]. Molecular profiling research in
the last decade has revealed breast cancer to be a heterogeneous
disease [2–4], motivating the development of molecular classifiers
of breast cancer sub-types to influence diagnosis, prognosis, and
treatment.
In 2002, a research study reported a molecular predictor of
breast cancer survival [5] based on analysis of gene expression
profiles from 295 breast cancer patients with 5 year clinical follow-
up. Based on these results, two independent companies developed
the commercially available MammaPrint [6] and Oncotype DX
[7] assays, which have both been promising in augmenting risk
prediction compared to models based only on clinical data.
However, their role in clinical decision-making is still being
debated.
Based on the success of these initial molecular profiles, a large
number of additional signatures have been proposed to identify
markers of breast cancer tumor biology that may affect clinical
outcome [8–13]. Meta-analyses indicate that many of them
perform very similarly in terms of risk prediction, and can often
be correlated with markers of cell proliferation [14], a well-known
predictor of patient outcome [15], especially for ER+ tumors
[16,17]. Therefore, it is much more challenging to identify
signatures that provide additional independent and more specific
risk prediction performance once accounting for proliferation and
clinical factors. Recent studies have even suggested that most
random subsets of genes are significantly associated with breast
cancer survival, and that the majority (60%) of 48 published
signatures did not perform significantly better than models built
from the random subsets of genes [18]. Correcting for the
confounding effect of proliferation based on an expression marker
of cell proliferation removes most of the signal from the 48
published signatures [18].
The difficulties in reaching community consensus regarding the
best breast cancer prognosis signatures illustrates a more intrinsic
problem whereby researchers are responsible for both developing
a model and comparing its performance against alternatives [19].
This phenomenon has been deemed the ‘‘self-assessment trap’’,
referring to the tendency of researchers to unintentionally or
intentionally report results favorable to their model. Such self-
assessment bias may arise, for example, by choosing assessment
statistics for which their model is likely to perform well, selective
reporting of performance in the modeling niche where their
method is superior, or increased care or expertise in optimizing
performance of their method compared to others.
In this work, we explore the use of a research strategy of
collaborative competitions as a way to overcome the self-
assessment trap. In particular, the competitive component
formally separates model development from model evaluation
and provides a transparent and objective mechanism for ranking
models. The collaborative component allows models to evolve and
improve through knowledge sharing, and thereby emphasizes
correct and insightful science as the primary objective of the study.
The concept of collaborative competitions is not without
precedent and is most evident in crowd-sourcing efforts for
harnessing the competitive instincts of a community. Netflix [20]
and X-Prize [21] were two early successes in online hosting of data
challenges. Commercial initiatives such as Kaggle [22] and
Innocentive [23] have hosted many successful online modeling
competitions in astronomy, insurance, medicine, and other data-
rich disciplines. The MAQC-II project [24] employed blinded
evaluations and standardized datasets in the context of a large
consortium-based research study to assess modeling factors related
to prediction accuracy across 13 different phenotypic endpoints.
Efforts such as CASP [25], DREAM [26], and CAFA [27] have
created communities around key scientific challenges in structural
biology, systems biology, and protein function prediction, respec-
tively. In all cases it has been observed that the best crowd-sourced
models usually outperform state-of-the-art off-the-shelf methods.
Despite their success in achieving models with improved
performance, existing resources do not provide a general solution
for hosting open-access crowd-sourced collaborative competitions
due to two primary factors. First, most systems provide partic-
ipants with a training dataset and require them to submit a vector
of predictions for evaluation in the held-out dataset [20,22,24,26],
often requiring (only) the winning team to submit a description of
their method and sometimes source code to verify reproducibility.
While this achieves the goal of objectively assessing models, we
believe it fails to achieve an equally important goal of developing a
transparent community resource where participants work openly
to collaboratively share and evolve models. We overcome this
problem by developing a system where participants submit models
as re-runnable source code by implementing a simple program-
matic API consisting of a train and predict method. Second, some
existing systems are designed primarily to leverage crowd-sourcing
to develop models for a commercial partner [22,23] who pays to
run the competition and provides a prize to the developer of the
best-performing model. Although we support this approach as a
creative and powerful method for advancing commercial applica-
tions, such a system imposes limitations on the ability of
participants to share models openly as well as intellectual property
restrictions on the use of models. We overcome this problem by
making all models available to the community through an open
source license.
Author Summary
We developed an extensible software framework for
sharing molecular prognostic models of breast cancer
survival in a transparent collaborative environment and
subjecting each model to automated evaluation using
objective metrics. The computational framework present-
ed in this study, our detailed post-hoc analysis of hundreds
of modeling approaches, and the use of a novel cutting-
edge data resource together represents one of the largest-
scale systematic studies to date assessing the factors
influencing accuracy of molecular-based prognostic mod-
els in breast cancer. Our results demonstrate the ability to
infer prognostic models with accuracy on par or greater
than previously reported studies, with significant perfor-
mance improvements by using state-of-the-art machine
learning approaches trained on clinical covariates. Our
results also demonstrate the difficultly in incorporating
molecular data to achieve substantial performance im-
provements over clinical covariates alone. However,
improvement was achieved by combining clinical feature
data with intelligent selection of important molecular
features based on domain-specific prior knowledge. We
observe that ensemble models aggregating the informa-
tion across many diverse models achieve among the
highest scores of all models and systematically out-
perform individual models within the ensemble, suggest-
ing a general strategy for leveraging the wisdom of crowds
to develop robust predictive models.
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In this study, we formed a research group consisting of scientists
from 5 institutions across the United States and conducted a
collaborative competition to assess the accuracy of prognostic
models of breast cancer survival. This research group, called the
Federation, was set up as a mechanism for advancing collaborative
research projects designed to demonstrate the benefit of team-
oriented science. The rest of our group consisted of the organizers
of the DREAM project, the Oslo team from the Norwegian Breast
Cancer study, and leaders of the Molecular Taxonomy of Breast
Cancer International Consortium (METABRIC), who provided a
novel dataset consisting of nearly 2,000 breast cancer samples with
median 10-year follow-up, detailed clinical information, and
genome-wide gene expression and copy number profiling data.
In order to create an independent dataset for assessing model
consistency, the Oslo team generated novel copy number data on
an additional 102 samples (the MicMa cohort), which was
combined with gene expression and clinical data for the same
samples that was previously put in the public domain by the same
research group [4,28].
The initial study using the METABRIC data focused on
unsupervised molecular sub-class discovery [29]. Although some of
the reported sub-classes do correlate with survival, the goal of this
initial work was not to build prognostic models. Indeed, the
models developed in the current study provide more accurate
survival predictions than those trained using molecular sub-classes
reported in the original work. Therefore, the current study
represents the first large-scale attempt to assess prognostic models
based on a dataset of this scale and quality of clinical information.
The contributions of this work are two-fold. First, we conducted
a detailed post-hoc analysis of all submitted models to determine
model characteristics related to prognostic accuracy. Second, we
report the development of a novel computational system for
hosting community-based collaborative competitions, providing a
generalizable framework for participants to build and evaluate
transparent, re-runnable, and extensible models. Further, we
suggest elements of study design, dataset characteristics, and
evaluation criteria used to assess whether the results of a
competition-style research study improve on standard approaches.
We stress that the transparency enabled by making source code
available and providing objective pre-defined scoring criteria allow
researchers in future studies to verify reproducibility, improve on
our findings, and assess their generalizability in future applications.
Thus the results and computational system developed in this work
serve as a pilot study for an open community-based competition
on prognostic models of breast cancer survival. More generally, we
believe this study will serve as the basis for additional competition-
based research projects in the future, with the goal of promoting
increased transparency and objectivity in genomics research (and
other applications) and providing an open framework to collab-
oratively evolve complex models leading to patient benefit, beyond




We used the METABRIC dataset as the basis of evaluating
prognostic models in this study. This dataset contains a total of
nearly 2,000 breast cancer samples. 980 of these samples
(excluding those with missing survival information) were available
for the duration of the collaborative competition phase of this
study. An additional 988 samples became available after we had
concluded our evaluation in the initial dataset and, fortunately,
served as a large additional dataset for assessing the consistency of
our findings. For each sample, the dataset contains median 10 year
follow-up, 16 clinical covariates (Table 1), and genome-wide gene
expression and copy number profiling data, normalized as
described in [29], resulting in 48,803 gene expression features
and 31,685 copy number features summarized at the gene level
(see Methods).
Initial analysis was performed to confirm that the data
employed in the competition were consistent with previously
published datasets and to identify potential confounding factors
such as internal subclasses. Data-driven, unsupervised hierarchical
clustering of gene expression levels revealed the heterogeneity of
the data and suggested that multiple subclasses do exist (not
shown) [29]. However, for the current analysis we decided to focus
on the well established separation into basal, luminal, and HER2
positive subclasses, as previously defined [2,30]. These subclasses
are known to closely match clinical data in the following way: most
triple-negative samples belong to the basal subclass; most ER
positive samples belong to the luminal subclass; and most ER
negative HER2 positive samples belong to the HER2 subclass. To
ensure that this holds in the current dataset, the 50 genes that best
separate the molecular subclasses in the Perou dataset [31]
(PAM50) were used for hierarchical clustering of the METABRIC
data and compared with a similar clustering of the Perou dataset
(Figure 1A). The results of the supervised clustering reveal similar
subclasses with similar gene expression signatures as those
presented by Perou et al, and were also consistent with the
clinical definitions as presented above. Finally, the 3 subclasses
show a distinct separation in their Kaplan-Meier overall survival
plots for the three subtypes defined by the clinical data, where the
HER2 subclass has the worst prognosis, followed by the basal
subclass, and the luminal subclass has the best prognosis, as
expected (Figure 1B). This analysis shows that sub-classification
based on ER (IHC), PR (gene expression), and HER2 (copy
number) should capture the major confounding factors that may
be introduced by the heterogeneity of the disease.
Multiple individual clinical features exhibit high correlation
with survival for non-censored patients, and have well documented
prognostic power (Table 1, Figure 1C), while others have little
prognostic power (Figure 1D). To demonstrate that the compe-
tition data is consistent in this respect, a Cox proportional hazard
model was fit to the overall survival (OS) of all patients using each
one of the clinical covariates individually. As expected, the most
predictive single clinical features are the tumor size, age at
diagnosis, PR status, and presence of lymph node metastases
(Table 1). To assess the redundancy of the clinical variables, an
additional multivariable Cox proportional hazard model was fit to
the overall survival (OS) of all patients using all clinical features.
The remaining statistically significant covariates were patient age
at diagnosis (the most predictive feature), followed by tumor size,
presence of lymph node metastases, and whether the patient
received hormone therapy.
Improving breast cancer models in the pilot competition
Participants from our 5 research groups were provided data
from 500 patient samples used to train prognostic models. These
models were submitted as re-runnable source code and partici-
pants were provided real-time feedback in the form of a
‘‘leaderboard’’ based on the concordance index of predicted
survival versus the observed survival in the 480 held-out samples.
Participants independently submitted 110 models to predict
survival from the supplied clinical and molecular data (Table S1),
showing a wide variability in their performance, which was
expected since there were no constraints on the submissions. Post-
hoc analysis of submitted models revealed 5 broad classes of
Breast Cancer Survival Modeling
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modeling strategies based on if the model was trained using: only
clinical features (C); only molecular features (M); molecular and
clinical features (MC); molecular features selected using prior
knowledge (MP); molecular features selected using prior knowl-
edge combined with clinical features (MPC) (Table 2). The
complete distribution of the performance of all the models,
evaluated using concordance index, and classified into these
categories is shown in Figure 2.
Analysis of the relative performance among model categories
suggested interesting patterns related to criteria influencing model
performance. The traditional method for predicting outcome is
Cox regression on the clinical features [32]. This model, which
used only clinical features, served as our baseline, and obtained a
concordance index of 0.6347 on the validation set. Models trained
on the clinical covariates using state-of-the-art machine learning
methods (elastic net, lasso, random forest, boosting) achieved
notable performance improvements over the baseline Cox
regression model (Figure 2, category ‘C’).
Two submitted models were built by naively inputting all
molecular features into machine learning algorithms (i.e. using all
gene expression and CNA features and no clinical features). These
models (our category ‘M’) both performed significantly worse than
the baseline clinical model (median concordance index of 0.5906).
Given that our training set contains over 80,000 molecular
features and only 500 training samples, this result highlights the
challenges related to overfitting due to the imbalance between the
number of features and number of samples, also known as the
curse of dimensionality [33,34].
Models trained using molecular feature data combined with
clinical data (category ‘MC’) outperformed the baseline clinical
model in 10 out of 28 (36%) submissions, suggesting there is
some difficulty in the naı¨ve incorporation of molecular feature
data compared to using only clinical information. In fact, the
best MC model attributed lower weights to molecular compared
to clinical features by rank-transforming all the features
(molecular and clinical) and training an elastic net model,
imposing a penalty only on the molecular features and not on the
clinical ones, such that the clinical features are always included
in the trained model. This model achieved a concordance index
of 0.6593, slightly better than the best-performing clinical only
model.
One of the most successful approaches to addressing the curse of
dimensionality in genomics problems has been to utilize domain-
specific prior knowledge to pre-select features more likely to be
associated with the phenotype of interest [35]. Indeed, the
majority of submitted models (66 of 110, 60%) utilized a strategy
of pre-selecting features based on external prior knowledge.
Interestingly, analysis of model submission dates indicates that
participants first attempted naı¨ve models incorporating all
molecular features, and after achieving small performance
improvements over clinical only models, evolved to incorporate
prior information as the dominant modeling strategy in the later
phase of the competition (Figure 2B). This observation is consistent
with previous reports highlighting the importance of real-time
feedback in motivating participants to build continuously improv-
ing models [36].
Table 1. Association of clinical features with overall survival (OS).
Variable name spearman(SP) SP p-val univariate HR uni p-val multivariate HR multi p-val
ageDiagnosis 20.05 2.34e-01 1.03 6.71e-07 1.05 3.98e-10
tumorSizeCM 20.19 1.47e-05 1.16 2.86e-07 1.1 4.74e-03
Lymphnodes (pos vs. neg) 0.24 4.2e-08 1.68 1.84e-04 1.62 5.2e-03
Hormone (treatment vs. no
treatment)
20.09 3.96e-02 1 9.84e-01 0.63 8.72e-03
Radiation (treatment vs. no
treatment)
20.04 3.62e-01 0.84 2.08e-01 0.7 2.19e-02
PR (pos vs. neg) 0.23 2.52e-07 0.53 4.21e-06 0.7 3.44e-02
Grade (ordinal) 20.15 1.02e-03 2.48 5.79e-03 1.98 5.63e-02
Chemo (treated vs not) 20.27 5.62e-10 1.62 3.06e-03 1.67 7.37e-02
HER2 (pos vs. neg) 20.1 2.50e-02 1.78 2.79e-03 1.43 1.84e-01
hist Medullary (vs. ILC) 20.04 3.6e-01 1.12 8.58e-01 0.62 4.77e-01
hist Mixed (vs. ILC) 0.06 1.63e-01 0.59 1.61e-01 0.83 6.36e-01
ER (pos. vs. neg) 0.14 1.23e-03 0.65 7.78e-03 0.8 7.73e-01
tripleNegative 20.09 4.05e-02 1.32 1.42e-01 0.89 7.75e-01
hist Inf Duct (vs. ILC) 20.04 3.89e-01 1.07 8.17e-01 0.93 7.99e-01
hist Muc (vs. ILC) 0 9.38e-01 0.92 8.75e-01 0.9 8.53e-01
ERPR 0.14 1.18e-03 0.65 8.26e-03 1.13 8.78e-01
The columns are: variable name; Spearman correlation between variable and OS for uncensored patients; p-value of the Spearman correlation; Cox proportional hazard
ratio (HR) for all patients between individual clinical features and OS; p-values of the HR (Wald test); HR for all patients using all clinical variables and OS; p-value (Wald
test) for the HR using all clinical features. The clinical covariates in this table include age at diagnosis (continuous), tumor size in centimeters (continuous), histological
grade (ordinal) and whether the patient received hormone therapy (treated vs. untreated), radiotherapy (treated vs. untreated), or chemotherapy (treated vs. untreated).
In addition, there are clinical covariates for common breast cancer subtype markers including HER2 status (positive vs. negative), ER status (positive vs. negative) and PR
status (positive vs. negative) individually, as well as joint ER and PR status (ERPR) and triple negative status (tripleNegative) when a patient is negative for ER, PR, and
HER. Histological types are: medullary carcinomas, mixed invasive, infiltrating ductal carcinomas (IDC), mucinous carcinomas, and infiltrating lobular carcinomas.
Histology is treated as a categorical level variable, with ILC as the baseline. The multivariate Cox model also includes site as a categorical level variable to adjust for
inclusion site (not reported). In the multivariate analyses ER status/endocrine treatment and chemotherapy/node status will be confounded. The table is sorted on the
p-values of the multivariate analysis.
doi:10.1371/journal.pcbi.1003047.t001
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All models trained on only the molecular features (i.e. excluding
the clinical features) and incorporating prior knowledge (MP
category) performed worse than the baseline model, with the
highest concordance index being 0.5947, further highlighting the
difficultly in using molecular information alone to improve
prognostic accuracy compared to clinical data.
Twenty-four models outperformed the baseline by combining
clinical features with molecular features selected by prior
knowledge (MPC category). The overall best-performing model
attained a concordance index of 0.6707 by training a machine
learning method (boosted regression) on a combination of: 1)
clinical features; 2) expression levels of genes selected based on
both data driven criteria and prior knowledge of their involvement
in breast cancer (the MASP feature selection strategy, as described
in Methods); 3) an aggregated ‘‘genomic instability’’ index
calculated from the copy number data (see Methods).
The wide range of concordance index scores for models in the
MPC category raises the question of whether the improved
performance of the best MPC models are explained by the
biological relevance of the selected features or simply by random
fluctuations in model scores when testing many feature sets. Due to
the uncontrolled experimental design inherent in accepting
unconstrained model submissions, additional evaluations are
needed to assess the impact of different modeling choices in a
controlled experimental design. We describe the results of this
experiment next.
Controlled experiment for model evaluation
We analyzed the modeling strategies utilized in the original
‘‘uncontrolled’’ model submission phase and designed a ‘‘con-
trolled’’ experiment to assess the associations of different modeling
choices with model performance. We determined that most
models developed in the uncontrolled experiment could be
described as the combination of a machine learning method with
a feature selection strategy. We therefore tested models trained
using combinations of a discrete set of machine learning methods
crossed with feature selection strategies using the following
experimental design:
1. We designed 15 categories of models based on the choice of
features used in each model based on the following design:
a. We chose 6 strategies for pre-selecting feature subsets as
developed in the uncontrolled phase (Table 3).
b. We created 6 additional model categories consisting of each
feature subset plus all clinical covariates.
c. We created an additional model category using only clinical
covariates.
d. We created 2 additional categories incorporating the genomic
instability index (GII), which was a component of the best-
performing model in the uncontrolled phase. We used GII in
additional to all clinical covariates, as well as GII in addition
to all clinical covariates and the additional features used in the
best-performing model (MASP) from the uncontrolled
experiment. We note that since GII is only a single feature
we did not train models using GII alone.
2. For each of the 15 feature selection strategies described above,
we trained 4 separate models using the machine learning
algorithms that were frequently applied and demonstrated
good performance in the uncontrolled experiment: boosting,
random survival forest, lasso, and elastic net.
3. We constructed a series of ensemble learning algorithms by
computing concordance index scores after averaging the rank
predictions of subsets of models. Models trained using
ensemble strategies included:
a. 15 ensemble models combining the learning algorithms for
each model category.
b. 4 ensemble models combining the model categories for each
learning algorithm.
c. 1 ensemble model combining all model categories and
learning algorithms.
This experiment design resulted in a total of 60 models based on
combinations of modeling strategies from the uncontrolled
Figure 1. Gene expression subclass analysis. (A) Comparison of hierarchical clustering of METABRIC data (left panel) and Perou data (right
panel). Hierarchical clustering on the gene expression data of the PAM50 genes in both datasets reveals a similar gene expression pattern that
separates into several subclasses. Although several classes are apparent, they are consistent with sample assignment into basal-like, Her2-enriched
and luminal subclasses in the Perou data. Similarly, in the METABRIC data the subclasses are consistent with the available clinical data for triple-
negative, ER and PR status, and HER2 positive. (B) Kaplan-Meier plot for subclasses. The METABRIC test dataset was separated into 3 major subclasses
according to clinical features. The subclasses were determined by the clinical features: triple negative (red); ER or PR positive status (blue); and HER2
positive with ER and PR negative status (green). The survival curve was estimated using a standard Kaplan-Meier curve, and shows the expected
differences in overall survival between the subclasses. (C,D) Kaplan-Meier curve by grade and histology. The test dataset was separated by tumor
grade (subplot C; grade 1 – red, grade 2 – green, grade 3- blue), or by histology (subplot D; Infilitrating Lobular – red, Infiltrating Ductal – yellow,
Medullary –green, Mixed Histology – blue, or Mucinous - purple). The survival curves were estimated using a standard Kaplan-Meier curve, and show
the expected differences in overall survival for the clinical features.
doi:10.1371/journal.pcbi.1003047.g001
Table 2. Description of categories of models submitted to the pilot competition based on the features used by the models in each
category.
Category Features used by models # models Range of c-index (median)
C Only clinical (C) features 14 0.5097–0.6576 (0.6264)
M Only molecular (M) features 2 0.5705–0.6108 (0.5906)
MC Molecular and clinical features 28 0.5334–0.6593 (0.6169)
MP Molecular features selected using prior (P) knowledge 8 0.5651–0.5947 (0.5806)
MPC Molecular features selected as above and all clinical features 58 0.5376–0.6707 (0.6197)
doi:10.1371/journal.pcbi.1003047.t002
Breast Cancer Survival Modeling
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experiment (Table S4), plus 20 models using ensemble strategies.
This controlled experimental design allowed us to assess the effect
of different modeling choices while holding other factors constant.
Following an approach suggested in the MAQC-II study [24],
we designed negative and positive control experiments to infer
bounds on model performance in prediction problems for which
models should perform poorly and well, respectively. As a negative
control, we randomly permuted the sample labels of the survival
data, for both the training and test datasets, and computed the
concordance index of each model trained and tested on the
permuted data. To evaluate how the models would perform on a
relatively easy prediction task, we conducted a positive control
experiment in which all models were used to predict the ER status
of the patients based on selected molecular features (excluding the
ER expression measurement). We found that all negative control
models scored within a relatively tight range of concordance
indices centered around 0.5 (minimum: 0.468, maximum: 0.551),
significantly lower than the lowest concordance index (0.575) of
any model trained on the real data in this experiment. Conversely,
all ER-prediction models scored highly (minimum: 0.79, maxi-
mum: 0.969), suggesting that the scores achieved by our survival
models (maximum: 0.6707) are not due to a general limitation of
the selected modeling strategies but rather the difficulty of
modeling breast cancer survival.
Overall, we found that the predictive performance of the
controlled experiment models (Figure 3A) was significantly
dependent on the individual feature sets (P = 1.02e-09, F-test),
and less dependent on the choice of the statistical learning
algorithm (P = 0.23, F-test). All model categories using clinical
covariates outperformed all model categories trained excluding
clinical covariates, based on the average score across the 4 learning
algorithms. The best-performing model category selected features
based on marginal correlation with survival, further highlighting
the difficulty in purely data-driven approaches, and the need to
Table 3. Feature sets used in the controlled experiment.
Feature Category Description
Clinical The set of 14 clinical features from [29].
Marginal Association 1000 molecular features (gene expression and/or copy number) most predictive of survival in a
univariate Cox regression analysis on the training set.
Top-Varying 1000 molecular features (gene expression and/or copy number) with the greatest variance in the
training set.
Cancer Census 1526 gene expression and copy number features corresponding to 487 genes from the Cancer
Gene Census database [60].
Higgins 1000 gene expression and copy-number features with the greatest variance among oncogenes
identified by Higgins et al. [61].
Metabric Clustering 754 gene expression and copy number features used to define the clusters in the study by Curtis
et al. [29].
MASP: Marginal Association with Subsampling and
Prior Knowledge
Gene expression of 50 known oncogenes and transcription factors selected by computing
univariate Cox regression models on random subsets of the training set and aggregating the
resulting p-values (see Methods).
GII: Genomic Instability Index Number of amplified/deleted sites as calculated from the segmented copy number data (see
Methods).
doi:10.1371/journal.pcbi.1003047.t003
Figure 2. Distribution of concordance index scores of models submitted in the pilot competition. (A) Models are categorized by the type
of features they use. Boxes indicate the 25th (lower end), 50th (middle red line) and 75th (upper end) of the scores in each category, while the whiskers
indicate the 10th and 90th percentiles of the scores. The scores for the baseline and best performer are highlighted. (B) Model performance by
submission date. In the initial phase of the competition, slight improvements over the baseline model were achieved by applying machine learning
approaches to only the clinical data (red circles), whereas initial attempts to incorporate molecular data significantly decreased performance (green,
purple, and black circles). In the intermediate phase of the competition, models combining molecular and clinical data (green circles) predominated
and achieved slightly improved performance over clinical only models. Towards the end of the competition, models combining clinical information
with molecular features selected based on prior information (purple circles) predominated.
doi:10.1371/journal.pcbi.1003047.g002
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incorporate prior knowledge to overcome the curse of dimension-
ality.
The best-performing model used a random survival forest
algorithm trained by combining the clinical covariates with a
single additional aggregate feature, called the genomic instability
index (GII), calculated as the proportion of amplified or deleted
sites based on the copy number data. This result highlights the
importance of evaluating models using a controlled experimental
design, as the best-performing method in the uncontrolled
experiment combined clinical variables with GII in addition to
selected gene expression features (clinical variables plus only GII
was not evaluated), and the controlled experiment pointed to
isolating GII as the modeling insight associated with high
prediction accuracy.
The random survival forest trained using clinical covariates and
GII was significantly better than a random survival forest trained
using clinical covariates alone (P = 2e-12 by paired Wilcoxon
signed rank test based on 100 bootstrap samples with replacement
from the test dataset). We also tested if inclusion of the GII feature
improved model performance beyond a score that could be
obtained by chance based on random selection of features. We
trained 100 random survival forest models and 100 boosting
models, each utilizing clinical information in addition to random
selections of 50 molecular features (corresponding to the number
of features used based on the MASP strategy, which achieved the
highest score of all feature selection methods). The best-
performing model from our competition (trained using clinical
covariates and GII) achieved a higher score than each of these 100
models for both learning algorithms (P,= .01).
The use of the aggregate GII feature was based on previous
reports demonstrating the association between GII and poor
prognosis breast cancer subtypes like Luminal B, HER2+ and
Basal-like tumors [37]. We found that HER2+ tumors had the
strongest association with the GII score (P = 1.65e-12, t-test) which
partly explains why it performs so well considering none of the
patients were treated with compounds that target the HER2
pathway (e.g. Herceptin). Samples with high GII scores were also
associated with high-grade tumors (P = 7.13e-13, t-test), further
strengthening its credential as a good survival predictor. However,
despite these strong associations, the genomic instability index
provided an added value to the strength of predictions even as
clinical covariates histologic grade and HER2 status are used in
the models.
Boosting was the best-performing method on average. Elastic
net and lasso exhibited stable performance across many feature
sets. Random survival forests performed very well when trained on
a small number of features based on clinical information and the
genomic instability index. However, their performance decreased
substantially with the inclusion of large molecular feature sets.
Ensemble methods trained by averaging predicted ranks across
multiple methods systematically performed better than the average
concordance index scores of the models contained in the
ensemble, consistent with previously reported results [38].
Strikingly, an ensemble method aggregating all 60 models
achieved a concordance index score of .654, significantly greater
than the average of all model scores (.623) (Figure 3B). The
ensemble performed better than the average model score for each
of 100 resampled collections of 60 models each, using boot-
strapping to sample with replacement from all 60 models
(P,= .01). The ensemble model scored better than 52 of the 60
(87%) models that constituted the ensemble. We note that 2 of the
algorithms (boosting and random forests) utilize ensemble learning
strategies on their own. For both of the other 2 algorithms (lasso
and elastic net) the method trained on an ensemble of the 15
feature sets scored higher than each of the 15 models trained on
the individual feature sets (Figure 3B). Consistent with previous
reports, the systematic outperformance of ensemble models
compared to their constituent parts suggests that ensemble
approaches effectively create a consensus that enhances the
biologically meaningful signals captured by multiple modeling
approaches. As previously suggested in the context of the DREAM
project [38–41], our finding further reinforces the notion that
crowd-sourced collaborative competitions are a powerful frame-
work for developing robust predictive models by training an
ensemble model aggregated across diverse strategies employed by
participants.
Consistency of results in independent datasets
In the first round of the competition, we did not restrict the
number of models a participant could submit. This raises the
possibility of model overfitting to the test set used to provide real-
time feedback. We therefore used 2 additional datasets to evaluate
Figure 3. Model performance by feature set and learning algorithm. (A) The concordance index is displayed for each model from the
controlled experiment (Table S4). The methods and features sets are arranged according to the mean concordance index score. The ensemble
method (cyan curve) infers survival predictions based on the average rank of samples from each of the four other learning algorithms, and the
ensemble feature set uses the average rank of samples based on models trained using all of the other feature sets. Results for the METABRIC2 and
MicMa datasets are show in Figure S1. (B) The concordance index of models from the controlled phase by type. The ensemble method again utilizes
the average rank for models in each category.
doi:10.1371/journal.pcbi.1003047.g003
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the consistency of our findings. The first dataset, which we called
METABRIC2, consisted of the 988 samples (excluding those with
missing survival data) from the METABRIC cohort that were not
used in either the training dataset or the test dataset used for real-
time evaluation. The second dataset, called MicMa, consisted of
102 samples with gene expression, clinical covariates, and survival
data available [4,28] and copy number data presented in the
current study (see Methods). We used the models from our
controlled experiment, which were trained on the original 500
METABRIC samples, and evaluated the concordance index of the
survival predictions of each model compared to observed survival
in both METABRIC2 and MicMa.
The concordance index scores across models from the original
evaluation were highly consistent in both METABRIC2 and
MicMa. The 60 models evaluated in the controlled experiment (15
feature sets used in 4 learning algorithms) had Pearson correlations
of .87 (P,1e-10) compared to METABRIC2 (Figure 4A) and .76
(P,1e-10) compared to MicMa (Figure 4C), although we note that
p-values may be over-estimated due to smaller effective sample
sizes due to non-independence of modeling strategies. Model
performance was also strongly correlated for each different
algorithm across the feature sets for both METABRIC2
(Figure 4B) and MicMa (Figure 4D).
Consistent with results from the original experiment, the top
scoring model, based on average concordance index of the
METABRIC2 and MicMa scores, was a random survival forest
trained using clinical features in combination with the GII. The
second best model corresponded to the best model from the
uncontrolled experiment (3rd best model in the controlled
experiment), and used clinical data in combination with GII and
the MASP feature selection strategy, and was trained using a
boosting algorithm. A random forest trained using only clinical
Figure 4. Consistency of results in 2 additional datasets. (A,C) Concordance index scores for all models evaluated in the controlled
experiment. Scores from the original evaluation are compared against METABRIC2 (A) and MicMa (C). The 4 machine learning algorithms are
displayed in different colors. (B,D) Individual plots for each machine learning algorithm.
doi:10.1371/journal.pcbi.1003047.g004
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data achieve the 3rd highest score. The top 39 models all
incorporated clinical data.
As an additional comparison, we generated survival predictions
based on published procedures used in the clinically approved
MammaPrint [6] and Oncotype DX [7] assays. We note that these
assays are designed specifically for early stage, invasive, lymph
node negative breast cancers (in addition ER+ in the case of
Oncotype DX) and use different scores calculated from gene
expression data measured on distinct platforms. It is thus difficult
to reproduce exactly the predictions provided by these assays or to
perform a fair comparison to the present methods on a dataset that
includes samples from the whole spectrum of breast tumors. The
actual Oncotype DX score is calculated from RT-PCR measure-
ments of the mRNA levels of 21 genes. Using z-score normalized
gene expression values from METABRIC2 and MicMa datasets,
together with their published weights, we recalculated Oncotype
DX scores in an attempt to reproduce the actual scores as closely
as possible. We then scored the resulting predictions against the
two datasets and obtained concordance indices of 0.6064 for
METABRIC2 and 0.5828 for MicMa, corresponding to the 81st
ranked model based on average concordance index out of all 97
models tested, including ensemble models and Oncotype DX and
MammaPrint feature sets incorporated in all learning algorithms
(see Table S5). Similarly, the actual MammaPrint score is
calculated based on microarray gene expression measurements,
with each patient’s score determined by the correlation of the
expression of 70 specific genes to the average expression of these
genes in patients with good prognosis (defined as those who have
no distant metastases for more than five years, ER+ tumors, age
less than 55 years old, tumor size less than 5 cm, and are lymph
node negative). Because of limitations in the data, we were not able
to compute this score in exactly the same manner as the original
assay (we did not have the metastases free survival time, and some
of the other clinical features were not present in the validation
datasets). We estimated the average gene expression profile for the
70 MammaPrint genes based on all patients who lived longer than
five years (with standardized gene expression data), then computed
each patient’s score as their correlation to this average good
prognosis profile. We scored the predictions against the two
validation datasets and observed concordance indices of 0.602 in
METABRIC2 and 0.598 in MicMa, corresponding to the 78th
ranked out of 97 models based on average concordance index.
We were able to significantly improve the scores associated with
both MammaPrint and Oncotype DX by incorporating the gene
expression features utilized by each assay as feature selection
criteria in our prediction pipelines. We trained each of the 4
machine learning algorithms with clinical features in addition to
gene lists from MammaPrint and Oncotype DX. The best-
performing models would have achieved the 8th and 26th best
scores, respectively, based on average concordance index in
METABRIC2 and MicMa. We note that using the ensemble
strategy of combining the 4 algorithms, the model trained using
Mammaprint genes and clinical data performed better than
clinical data alone, and achieved the 5th highest average model
score, including the top score in METABRIC2, slightly (.005
concordance index difference) better than the random forest
model using clinical data combined with GII, though only the 17st
ranked score in MicMa. This result suggests that incorporating the
gene expression features identified by these clinically implemented
assays into the prediction pipeline described here may improve
prediction accuracy compared to current analysis protocols.
An ensemble method, aggregating results across all learning
algorithms and feature sets, performed better than 71 of the 76
models (93%) that constituted the ensemble, consistent with our
finding that the ensemble strategy achieves performance among
the top individual approaches. For the 19 feature selection
strategies used in the METABRIC2 and MicMa evaluations, an
ensemble model combining the results of the 4 learning algorithms
performed better than the average of the 4 learning algorithms in
36 out of 38 cases (95%). Also consistent with our previous result,
for both algorithms that did not use ensemble strategies themselves
(elastic net and lasso), an ensemble model aggregating results
across the 19 feature sets performed better than each of the
individual 19 feature sets for both METABRIC2 and MicMa.
Taken together, the independent evaluations in 2 additional
datasets are consistent with the conclusions drawn from the
original real-time feedback phase of the completion, regarding
improvements gained from ensemble strategies and the relative
performance of models.
Discussion
‘‘Precision Medicine’’, as defined by the Institute of Medicine
Report last year, proposes a world where medical decisions will be
guided by molecular markers that ensure therapies are tailored to
the patients who receive them [42]. Moving towards this futuristic
vision of cancer medicine requires systematic approaches that will
help ensure that predictive models of cancer phenotypes are both
clinically meaningful and robust to technical and biological sources
of variation.
Despite isolated successful developments of molecular diagnostic
and personalized medicine applications, such approaches have not
translated to routine adoption in standard-of-care protocols. Even
in applications where successful molecular tests have been
developed, such as breast cancer prognosis [5,6], a plethora of
research studies have claimed to develop models with improved
predictive performance. Much of this failure has been attributed to
‘‘difficulties in reproducibility, expense, standardization and proof
of significance beyond current protocols’’ [43]. The propensity of
researchers to over-report the performance of their own
approaches has been deemed the ‘‘self-assessment trap’’ [19].
We propose community-based collaborative competitions [43–
49] as a general framework to develop and evaluate predictive
models of cancer phenotypes from high-throughput molecular
profiling data. This approach overcomes limitations associated
with the design of typical research studies, which may conflate
self-assessment with methodology development or, even more
problematic, with data generation. Thus competition-style
research may promote transparency and objective assessment of
methodologies, promoting the emergence of community stan-
dards of methodologies most likely to yield translational clinical
benefit.
The primary challenge of any competition framework is to
ensure that mechanisms are in place to prevent overfitting and
fairly assess model performance, since performance is only
meaningful if models are ranked based on their ability to capture
some underlying signal in the data. For example, such an
approach requires datasets affording sufficient sample sizes and
statistical power to make meaningful comparisons of many models
across multiple training and testing data subsets. We propose
several strategies for assessing if the results obtained from a
collaborative competition are likely to generalize to future
applications and improve on state-of-the art methodologies that
would be employed by an expert analyst.
First, baseline methods should be provided as examples of
approaches an experienced analyst may apply to the problem. In
our study, we employed a number of such methods for
comparison, including methodologies used in clinical diagnostic
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tests and multiple state-of-the-art machine learning methods
trained using only clinical covariates.
Second, performance of models should be evaluated in multiple
rounds of independent validation. In this study, we employed a
multi-phase strategy suggested by previous researchers [50] in
which a portion of the dataset is held back to provide real-time
feedback to participants on model performance and another
portion of the dataset is held back and used to score the
performance of all models, such that participants cannot overfit
their models to the test set. If possible, we recommend an
additional round of validation using a dataset different from the
one used in previous rounds, in order to test against the possibility
that good performance is due to modeling confounding variables
in the original dataset. This experimental design provides 3
independent rounds of model performance assessment, and
consistent results across these multiple evaluations provides strong
evidence that performance of the best approaches discovered in
this experimental design are likely to generalize in additional
datasets.
Finally, statistical permutation tests can provide useful safe-
guards against the possibility that improved model performance is
attributable to random fluctuations based on evaluation of many
models. Such tests should be designed carefully based on the
appropriate null hypothesis. A useful, though often insufficient, test
is to utilize a negative control null model, for example by
permuting the sample labels of the response variable. We suggest
that additional tests may be employed as post-hoc procedures
designed specifically to provide falsifiable hypotheses that may
provide alternative explanations of model performance. For
example, in this study we assessed the performance of many
models trained using the same learning algorithm (random
survival forest) and the same clinical features as used in the top
scoring model, but using random selections of molecular features
instead of the GII feature. This test was designed to falsify the
hypothesis that model performance is within the range of likely
values based on random selection of features, as has been a
criticism of previously reported models [18].
We suggest that the guidelines listed above provide a useful
framework in reporting the results of a collaborate competition,
and may even be considered necessary criteria to establish the
likelihood that findings will generalize to future applications. As
with most research studies, a single competition cannot compre-
hensively assess the full extent to which findings may generalize to
all potentially related future applications. Accordingly, we suggest
that a collaborative competition should indeed report the best
forming model, provided it meets the criteria listed above, but
need not focus on declaring a single methodology as conclusively
better than all others. By analogy to athletic competitions such as
an Olympic track race, a gold medal is given to the runner with
the fastest time, even if by a fraction of a second. Judgments of
superior athletes emerge through integrating multiple such data
points across many races against different opponents, distances,
weather conditions, etc., and active debate among the community.
A research study framed as a collaborative competition may
facilitate the transparency, reproducibility, and objective evalua-
tion criteria that provide the framework on which future studies
may build and iterate towards increasingly refined assessments
through a continuous community-based effort.
Within several months we developed and evaluated several
hundred modeling approaches. Our research group consisted of
experienced analysts trained as both data scientists and clinicians,
resulting in models representing state-of-the art approaches
employed in both machine learning and clinical cancer research
(Table 3). By conducting detailed post-hoc analysis of approaches
developed by this group, we were able to design a controlled
experiment to isolate the performance improvements attributable
to different strategies, and to potentially combine aspects of
different approaches into a new method with improved perfor-
mance.
The design of our controlled experiment builds off pioneering
work by the MAQC-II consortium, which compiled 6 microarray
datasets from the public domain and assessed modeling factors
related to the ability to predict 13 different phenotypic endpoints.
MAQC-II classified each model based on several factors (type of
algorithm, normalization procedure, etc), allowing analysis of the
effect of each modeling factor on performance. Our controlled
experiment follows this general strategy, and extends it in several
ways.
First, MAQC-II, and most competition-base studies [20,22,26],
accept submissions in the form of prediction vectors. We
developed a computational system that accepts models as re-
runnable source code implementing a simple train and predict
API. Source code for all submitted models are stored in the
Synapse compute system [51] and are freely available to the
community. Thus researchers may reproduce reported results,
verify fair play and lack of cheating, learn from the best-
performing models, reuse submitted models in related applications
(e.g. building prognostic models in other datasets), build ensemble
models by combining results of submitted models, and combine
and extend innovative ideas to develop novel approaches.
Moreover, storing models as re-runnable source code is important
in assessing the generalizability and robustness of models, as we
are able to re-train models using different splits or subsets of the
data to evaluate robustness, and we (or any researcher) can
evaluate generalizability by assessing the accuracy of a model’s
predictions in an independent dataset, such as existing related
studies [5] or emerging clinical trial data [52]. We believe this
software system will serve as a general resource that is extended
and re-used in many future competition-based studies.
Second, MAQC-II conducted analysis across multiple pheno-
typic endpoints, which allowed models to be re-evaluated in the
context of many prediction problems. However, this design
required models to be standardized across all prediction problems
and did not allow domain-specific insights to be assessed for each
prediction problem. By contrast, our study focused on the single
biomedical problem of breast cancer prognosis, and allowed
clinical research specialists to incorporate expert knowledge into
modeling approaches. In fact, we observed that feature selection
strategies based on prior domain-specific knowledge had a greater
effect on model performance than the choice of learning
algorithm, and learning algorithms that did not incorporate prior
knowledge were unable to overcome challenges with incorporating
high-dimensional feature data. In contrast to previous reports that
have emphasized abstracting away domain-specific aspects of a
competition in order to attract a broader set of analysis [50], in
real-word problems, we emphasize the benefit of allowing
researchers to apply domain-specific expertise and objectively test
the performance of such approaches against those of analysts
employing a different toolbox of approaches.
Finally, whereas MAQC-II employed training and testing splits
of datasets for model evaluation, our study provides an additional
level of evaluation in a separate, independent dataset generated on
a different cohort and using different gene expression and copy
number profiling technology. Consistent with findings reported by
MAQC-II, our study demonstrates strong consistency of model
performance across independent evaluations and provides an
important additional test of model generalizability that more
closely simulates real-world clinical applications, in which data is
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generated separately from the data used to construct models. More
generally, whereas MAQC-II evaluated multiple prediction
problems in numerous datasets with gene expression data and
samples numbers from 70 to 340, our study went deeper into a
evaluating a single prediction problem, utilizing copy number and
clinical information in addition to gene expression, and with a
dataset of 2,000 samples in addition to an independently-
generated dataset with 102 samples.
The model achieving top performance in both the initial
evaluation phase and the evaluation in additional datasets
combined a state-of-the-art machine learning approach (random
survival forest) with a clinically motivated feature selection strategy
that used all clinical features together with an aggregate genomic
instability index. Interestingly, this specific model was not tested in
the uncontrolled phase, and was the result of the attempt to isolate
and combine aspects of different modeling approaches in a
controlled experiment. The genomic instability index measure
may serve as a proxy for the degree to which DNA damage repair
pathways (including, for instance, housekeeping genes like p53 and
RB) have become dysregulated [37].
Beyond the specifics of the top performing models, we believe
the more significant contribution of this work is as a building
block, providing a set of baseline findings, computational
infrastructure, and proposed research methodologies used to
assess breast cancer prognosis models, and extending in the future
to additional phenotype prediction problems. Towards this end,
we have recently extended this work into an open collaborative
competition through which any researcher can freely register and
evaluate the performance of submitted models against all others
submitted throughout the competition. Though this expanded
breast cancer competition, and future phenotype prediction
competitions to be hosted as extensions of the current work, we
invite researchers to improve, refute, and extend our findings and
research methodologies to accelerate the long arc of cumulative
progress made by the community through a more transparent and
objectively assessed process.
Methods
Breast Cancer Prognosis Competition Design and
Software
Our competition was designed to assess the accuracy of
predicting patient survival (using the overall survival metric,
median 10 year follow-up) based on feature data measured in
the METABRIC cohort of 980 patients, including gene expression
and copy number profiles and 16 clinical covariates (Table 1).
Participants were given a training dataset consisting of data
from 500 samples, and data from the remaining 480 were hidden
from participants and used as a validation dataset to evaluate
submitted models.
We developed the computational infrastructure to support the
competition within the open-source Sage Synapse software
platform. Detailed documentation is available on the public
competition website: https://sagebionetworks.jira.com/wiki/
display/BCC/Home. The system is designed to generalize to
support additional community-based competitions and consists of
the following components (Figure 5):
1. The ability for participants to access training data stored in the
Sage Synapse software system through programmatic APIs,
with initial support built for the R programming language.
2. A programmatic API for training and testing predictive models.
To date, we have developed support for models developed in
the R programming language conforming to a simple interface
implementing methods named customTrain and customPre-
dict. Any model conforming to this interface can be plugged-in
to the competition infrastructure, trained on the training
dataset, and evaluated for prediction accuracy in the validation
dataset, as well as using various cross-validation statistics.
3. The ability to upload models, including re-runnable source
code, in Synapse, allowing models to be shared with the
community in a fully transparent, reproducible environment.
4. An automated model evaluation system for assessing the
performance of submitted models and outputting the scores to
a web-based real-time leaderboard. We stress this aspect of the
framework, based on the findings from previous competitions
that rapid feedback is critical to motivating its participants to
improve their model beyond the baseline [36].
5. Communication and social networking tools, such as wikis and
discussion forums (http://support.sagebase.org).
All models are available with downloadable source code using
the Synapse IDs displayed in Table S1 and Table S4. An
automated script continuously monitored for new submissions,
which were sent to worker nodes in a computational cluster for
scoring. Each worker node ran an evaluation script, which called
the submitted model’s customPredict method with arguments
corresponding to the gene expression, copy number, and clinical
covariate values in the held-out validation dataset. This function
returns a vector of predicted survival times in the validation
dataset, which were used to calculate the concordance index as a
measure of accuracy compared to the measured survival times for
Figure 5. Model evaluation pipeline schematic. Green regions:
Public areas, untrusted. Blue regions: Trusted areas where no
competitor’s code is to be run. Yellow region: Sandboxed area, where
untrusted code is run on a trusted system. Red region: Permissions
managed by Synapse.
doi:10.1371/journal.pcbi.1003047.g005
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the same samples. Concordance index scores were shown in a real-
time leaderboard, similar to the leaderboards displaying the
models scores shown in Table S1 and Table S4.
Concordance index (c-index) is the standard metric for
evaluation of survival models [53]. The concordance index ranges
from 0 in the case of perfect anti-correlation between the rank of
predictions and the rank of actual survival time through 0.5 in the
case of predictions uncorrelated with survival time to 1 in the case
of exact agreement with rank of actual survival time. We
implemented a method to compute the exact value of the
concordance index by exhaustively sampling all pairwise combi-
nations of samples rather than the usual method of stochastically
sampling pairwise samples. This method overcomes the stochastic
sampling used in standard packages for concordance index
calculation and provides a deterministic, exact statistic used to
compare models.
Study timeline
Data on the original 980 samples were obtained for this study in
early January, 2012. Study design and computational infrastruc-
ture were developed from then until March 14th, at which point
participants were given access to the 500 training samples and
given 1 month to develop models in the ‘‘uncontrolled experi-
ment’’ phase. During this time, participants were given real-time
feedback on model performance evaluated against the held-out
test set of 480 samples. After this 1-month model development
phase, all models were frozen and inspected by the group to
conduct post-hoc model evaluation and identify modeling
strategies used to design the controlled evaluation. All models in
the controlled evaluation were re-trained on the 500 training
samples and re-evaluated on the 480 test samples. After all
evaluation was completed based on the original 980 samples, the
METABRIC2 and MicMa datasets became available, and were
used to perform additional evaluations of all models, which was
conducted between January 2013–March 2013. For the new
evaluation, all data was renormalized to the gene level, as
described below, in order to allow comparison of models across
datasets performed on different platforms. Models were retrained
using the re-normalized data for the same 500 samples in the
original training set.
Model source code
All model source code is available in the subfolders of Synapse
ID syn160764, and specific Synapse IDs for each model are listed
in Table S1 and Table S4. Data stored in Synapse may be
accessed using the Synapse R client (https://sagebionetworks.jira.
com/wiki/display/SYNR/Home) or by clicking the download
icon on the web page corresponding to each model, allowing the
user to download a Zip archive containing the source files
contained in the submission.
Datasets and normalization
The METABRIC dataset used in the competition contains gene
expression data from the Illumina HT 12v3 platform and copy
number data derived from experiments performed on the
Affymetrix SNP 6.0 platform. In the initial round of analysis,
the first 980 samples data was normalized as described in [29],
corresponding to the data available in the European Genome-
Phenome Archive (http://www.ebi.ac.uk/ega), accession number
EGAS00000000083. Copy number data was summarized to the
gene level by calculating the mean value of the segmented regions
overlapping a gene. Data for use in our study are available in the
Synapse software system (synapse.sagebase.org) within the folder
with accession number syn160764 (https://synapse.prod.sagebase.
org/#!Synapse:syn160764), subject to terms of use agreements
described below. Data may be loaded directly in R using the
Synapse R client or downloaded from the Synapse web site.
Patients treated for localized breast cancer from 1995 to 1998 at
Oslo University Hospital were included in the MicMa cohort, and
123 of these had available fresh frozen tumor material [4,28].
Gene expression data for 115 cases obtained from an Agilent
whole human genome 4644 K one color oligo array was available
(GSE19783) [54]. Novel SNP-CGH data from 102 of the MicMa
samples were obtained using the Illumina Human 660k Quad
BeadChips according to standard protocol. Normalized LogR
values summarized to gene level were made available and are
accessible in Synapse (syn1588686).
All data used for the METABRIC2 and MicMa analyses are
available as subfolders of Synapse ID syn1588445. For comparison
of METABRIC2 and MicMa, we standardized all clinical
variables, copy number, and gene expression data across both
datasets. Clinical variables were filtered out that were not available
in both datasets. Data on clinical variables used in this comparison
are available in Synapse.
All gene expression datasets were normalized according the
supervised normalization of microarrays (snm) framework and
Bioconductor package [55,56]. Following this framework we
devised models for each dataset that express the raw data as
functions of biological and adjustment variables. The models were
built and implemented through an iterative process designed to
learn the identity of important variables. Once these variables
were identified we used the snm R package to remove the effects of
the adjustment variables while controlling for the effects of the
biological variables of interest.
SNP6.0 copy number data was also normalized using the snm
framework, and summarization of probes to genes was done as
follows. First, probes were mapped to genes using information
obtained from the pd.genomewidesnp.6 Bioconductor package [57].
For genes measured by two probes we define the gene-level values
as an unweighted average of the probes’ data. For genes measured
by a single probe we define the gene-level values as the data for the
corresponding probe. For those measured by more than 2 probes
we devised an approach that weights probes based upon their
similarity to the first eigengene. This is accomplished by taking a
singular value decomposition of the probe-level data for each gene.
The percent variance explained by the first eigengene is then
calculated for each probe. The summarized values for each gene
are then defined as the weighted mean with the weights
corresponding to the percent variance explained.
For Illumina 660k data we processed the raw files using the
crlmm bioconductor R package [58]. The output of this method
produces copy number estimates for more than 600k probes. Next,
we summarized probes to Entrez gene ids using a mapping file
obtained from the Illumina web site. For genes measured by more
than two probes we selected the probe with the largest variance.
Feature selection methods
Feature selection strategies used in the controlled experiment
(identified through post-hoc analysis of the uncontrolled experi-
ment) are described briefly in Table 3. Specific genes used in each
category are available within Synapse ID syn1643406 and can be
downloaded as R binaries via the Synapse web client or directly
loaded in R using the Synapse R client. Most feature selection
strategies are sufficiently described in Table 3, and we provide
additional details on 2 methods below.
The MASP (Marginal Association with Subsampling and Prior
Knowledge) algorithm employs the following procedure: all genes
were first scored for association with survival (using Cox
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regression) in chunks of 50 randomly selected gene expression
samples. This process was repeated 100 times which resulted in an
overall survival association score si~{
P
j log pij where pij is the
p-value associated with the Cox regression on the expression of
gene i in sample set j. All genes were sorted in descending order by
their survival association score and the top 50 oncogenes and
transcription factors were kept. A list of human transcription
factors was obtained from [59] and a list of oncogenes was
compiled by searching for relevant keywords against the Entrez
gene database.
GII is a measure of the proportion of amplified or deleted
genomic loci, calculated from the copy number data. Copy
number values are presented as segmented log-ratios cij with
respect to normal controls. Amplifications and deletions are thus













The data used in this study were collected and analyzed under
approval of an IRB [29]. The MicMa study was approved by the
Norwegian Regional Committee for medical research ethics,
Health region II (reference number S-97103). All patients have
given written consent for the use of material to research purposes.
Supporting Information
Figure S1 Performance of models from the controlled experi-
ment in the METABRIC2 (A) and MicMa (B) dataset.
(PNG)
Table S1 Complete details of all the models submitted to the
pilot competition in the uncontrolled experimental design. Source
code for all models are available using the Synapse IDs listed in
this table (see Methods for description of how to view model source
code).
(XLSX)
Table S2 Association of gene expression and CNA with survival
and p-values of the association between gene expression and
survival and between CNA and survival for the 10 probes with
lowest P-value. (a) Top ten gene expression probes associated with
survival marginally. (b) Top ten copy number probes associated
with survival marginally. (c) Top ten gene expression probes
associated with survival conditioning on clinical variables. (d) Top
ten copy number alteration probes associated with survival
conditioning on clinical variables.
(DOCX)
Table S3 Top 50 oncogenes and transcription factors inferred
by the MASP feature selection algorithm.
(XLSX)
Table S4 Complete details of all the models evaluated in the
controlled experiment. Source code for all models is available
using the Synapse IDs listed in this table.
(XLSX)
Table S5 Model scores in METABRIC2 and MicMa evalua-
tions. Models, and corresponding model scores, used in the
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